/ PORTFOLIO
Xilio-Logo_Full-Color-1024x683

Boston, MA

Xilio is an oncology company developing highly-potent, tumor-selective immunotherapies to improve patient outcomes. With an anti-CTLA4 antibody as validation, the company’s technology is also being applied to cytokines, which currently have limited or no clinical utility due to toxicities. By tailoring pharmacokinetic and pharmacodynamic properties in parallel, Xilio aims to design molecules with potential best-in-class potency and selectivity.

IPO October 2021 (NASDAQ: XLO)

logo-rivervest

© Copyright RiverVest® All Rights Reserved.